Industry Information

Update May 28, 2021

Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy sotrovimab for the treatment of mild-to-moderate COVID-19...

Update May 25, 2021

FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of...

Update May 19, 2021

FDA approves enzalutamide for metastatic castration-sensitive prostate cancer

On December 16, 2019, the Food and Drug Administration approved enzalutamide (XTANDI, Astellas Pharma Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC). FDA previously...

Update May 19, 2021

Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory...

Update May 19, 2021

FDA approves larotrectinib for solid tumors with NTRK gene fusions

On November 26, 2018, the Food and Drug Administration granted accelerated approval to larotrectinib (VITRAKVI, Loxo Oncology Inc. and Bayer) for adult and pediatric patients with solid tumors that...

Update April 01, 2021

COVID-19 Vaccine: Surmounting Prejudices and Other Roadblocks

Against all odds and contrary to expectations, Nigeria recently joined a few other African countries to take delivery of its much expected AstraZeneca-Oxford COVID-19 vaccine, manufactured by the...

Update April 01, 2021

UCSF and MGH: Apalutamide Delays Progression of Nonmetastatic, Castration-Resistant Prostate Cancer

BOSTON and SAN FRANCISCO, Feb. 8, 2018 /PRNewswire-USNewswire/ -- Treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with...

Update April 01, 2021

FDA approves new treatment for a type of late stage prostate cancer

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with...

Update April 01, 2021

Enzalutamide

Enzalutamide (Xtandi) is a type of hormone therapy for men with prostate cancer that has spread to other parts of the body (advanced prostate cancer). It is usually only offered to men whose prostate...

Update April 01, 2021

Enzalutamide or abiraterone?

Enzalutamide and abiraterone are both types of hormone therapy that treat advanced prostate cancer. Your hospital doctor will talk to you about which drug is most suitable for you. For example,...

Most Popular

Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19

FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

FDA approves enzalutamide for metastatic castration-sensitive prostate cancer

Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19

lastest New

ERLEADA® (Apalutamide) shows quickly, deeply and lastingly reduce the prostate specific antigen (PSA), with high compliance!

KRAS mutant lung cancer new drug: targeted drug Lumakras

AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis

Eli Lilly's oral JAK inhibitor Olumiant (Baritinib): 9.3 years of treatment, with long-term good safety!